LATS2 Antibody

中文名稱：

LATS2兔多克隆抗體
貨號(hào)：

CSB-PA008767
規(guī)格：

￥1090
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

Q9NRM7
基因名：

LATS2
別名：

FLJ13161 antibody; Kinase phosphorylated during mitosis protein antibody; KPM antibody; Large tumor suppressor homolog 2 antibody; Large tumor suppressor homolog 2 Drosophila antibody; Large tumor suppressor kinase 2 antibody; LATS large tumor suppressor Drosophila homolog 2 antibody; LATS large tumor suppressor homolog 2 antibody; Lats2 antibody; LATS2_HUMAN antibody; Serine/threonine kinase kpm antibody; Serine/threonine protein kinase kpm antibody; Serine/threonine-protein kinase kpm antibody; Serine/threonine-protein kinase LATS2 antibody; Warts like kinase antibody; Warts-like kinase antibody
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse
免疫原：

Synthesized peptide derived from the Internal region of Human Kpm.
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

IHC, IF, ELISA

推薦稀釋比：

Application	Recommended Dilution
IHC	1:100-1:300
IF	1:200-1:1000
ELISA	1:20000

Protocols：

Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
ELISA Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor. Phosphorylates SNAI1 in the nucleus leading to its nuclear retention and stabilization, which enhances its epithelial-mesenchymal transition and tumor cell invasion/migration activities. This tumor-promoting activity is independent of its effects upon YAP1 or WWTR1/TAZ.
基因功能參考文獻(xiàn)：
1. Knockdown of Lats1/2 prevented the cytoplasmic delocalization of Yap1/Taz proteins in response to AICAR. PMID: 29730476
2. USP9X is a deubiquitylase of the Hippo pathway kinase LATS2 and that the Hippo pathway functions as a downstream signaling cascade that mediates USP9X's tumor-suppressive activity. PMID: 29183995
3. Knockdown of LATS2 attenuated the suppression of FUS overexpression on hepatocellular carcinoma progression, and LATS2 expression was positively correlated with FUS expression in hepatocellular carcinoma tissues. PMID: 30308519
4. Study shows that LATS2 mRNA expression is remarkably downregulated in breast neoplasm while the protein expression level is absent. The absence of LATS2 protein strongly correlated with promoter hypermethylation and TNM staging. PMID: 30010037
5. LATS2 overexpression is associated with chronic myeloid leukemia. PMID: 29387948
6. The promotor methylation of LATS2 gene may play an important role in the occurrence of oral squamous cell carcinoma. PMID: 29972924
7. Results identified that miR-31 directly suppressed LATS2 expression, which inactivated TAZ and led to the subsequent action of esophageal squamous cell carcinoma (ESCC) tumorigenicity. Significantly, it was showed that LATS2 and its downstream gene TAZ highly correlated with ESCC progression with poor prognosis. PMID: 29145896
8. STK40 and LATS2 are conserved miR-31 target genes that have roles in regulation of keratinocyte growth and hair follicle biology PMID: 28419554
9. Genetic data coupled with transcriptomic data allowed the identification of a new malignant pleural mesothelioma (MPM)molecular subgroup, C2(LN), characterized by a co-occurring mutation in the LATS2 and NF2 genes in the same MPM. MPM patients of this subgroup presented a poor prognosis. Coinactivation of LATS2 and NF2 leads to loss of cell contact inhibition between MPM cells PMID: 28003305
10. LATS1/2 signaling via the Hippo pathway regulates human megakaryocytic differentiation. PMID: 27786336
11. Low LATS2 expression is associated with Liver Cancer. PMID: 28775168
12. The LATS2 is a prognostic biomarker and a tumour metastasis suppressor in hepatocellular carcinoma. PMID: 28247446
13. The findings reveal a novel signal upstream of PRC2, and provide insight into the crucial role of LATS2 in coordinating the epigenome through regulation of PRC2. PMID: 27434182
14. PVT1 recruits EZH2 to the large tumor suppressor kinase 2 (LATS2) promoter and represses LATS2 transcription. PMID: 26908628
15. findings reveal a non-canonical (that is, YAP/TAZ-independent) effect of LATS in the regulation of human breast cell fate PMID: 28068668
16. LATS2 as the direct target of miR-372 in prostate cancer cells. PMID: 27730751
17. overexpression of LATS2 resulted in mobility inhibition in non-small cell lung cancer cell lines A549 and H1299, and reduced protein level of matrix metalloproteinase-2 (MMP-2) and MMP-9. PMID: 27470365
18. LATS2 was found to have binding sites for miR-135b in the 3'UTR region and results demonstrated that LATS2 is a direct target of miR-135b which regulates its expression in breast cancer cells. PMID: 26934863
19. Characterisation of LATS2 variants uncovers novel insights into the regulation of LATS kinases in Hippo signalling. PMID: 26898830
20. LATS2 could be induced by TNF-alpha and inhibited cell proliferation and invasion by phosphorylating YAP in OSCC cells. PMID: 25782587
21. Mutation in LATS2 gene is associated with malignant peritoneal mesothelioma. PMID: 25798586
22. Phosphorylation of CHO1 at S716 by Lats2 regulate its centrosomal localization, and that phosphorylated CHO1 interacts with and activates LIMK1 during early mitosis. PMID: 25786116
23. Loss of LATS2 expression is associated with lung cancer. PMID: 25946971
24. results reported here further support that LATS1/2 act normally as tumor suppressors and loss of their functions contributes to human cancer development PMID: 25482410
25. Phosphorylation of S716 NDR/LATS, present only in the longest Kif23 isoform, is required for phosphorylation at S814, revealing phosphorylation at these two sites, and differential regulation of Kif23-14-3-3 interaction for the two Kif23 isoforms. PMID: 25658096
26. LATS1 and LATS2 kinases play an important role in the regulation of NS5A function through site-specific post-translational modification and that phosphorylation of Ser/Thr71 is essential for optimal viral genome replication. PMID: 25044019
27. miR-25/miR-107-LATS2 axis might play an important role in proliferation and invasion of the gastric cancer cells PMID: 25824045
28. Both LATS1 and LATS2 were not related with the clinical variables in mucinous and clear cell carcinoma PMID: 25841306
29. LATS2 expression level is predictive of survival in patients with resected lung AD. LATS2 may modulate and contribute to tumor growth via different signaling pathways in EGFR mutant and wild-type tumors. PMID: 24976335
30. LATS2 was found to negatively regulate NF-kappaB signaling in NSCLC cells. PMID: 25391426
31. LATS2 protein overexpression is a prognostic indicator for patients diagnosed with colorectal cancer. PMID: 24976283
32. miR-25 negatively regulated LATS2 expression and promoted OC cell growth and motility. PMID: 25179841
33. LATS2 over-expression is associated with acute myeloid leukemia. PMID: 24743869
34. NF2 loss-driven derepressed CRL4(DCAF1) promotes activation of YAP by inhibiting hippo pathwat kinases Lats1 and 2 in the nucleus. PMID: 25026211
35. LATS2 directly interacts with beta-catenin and disrupts beta-catenin iteraction with BCL9. PMID: 24360964
36. these results indicate that miR-181b promotes proliferation and invasion by targeting LATS2 in ovarian cancer cells. PMID: 24735543
37. Phosphorylation by Lats2 induces degradation of p21 and promotes apoptosis. Findings describe a novel Lats2-dependent mechanism for induction of cell death in response to severe DNA damage. PMID: 23886938
38. At low cell density, overexpression of the Hippo pathway kinase large tumor suppressor 2 (Lats2) inhibited c-Abl activity. PMID: 23852372
39. LATS1 and LATS2 mutations from cancers can lead to loss or reduction of their growth-inhibitory activity PMID: 24026096
40. These results collectively suggest that the Hippo pathway negatively regulates the actin-binding activity of Amot family members through direct phosphorylation. PMID: 24225952
41. Thus AMOT is a direct substrate of Lats1/2 mediating functions of the Hippo pathway in endothelial cell migration and angiogenesis. PMID: 24106267
42. Identifying novel kinases which modulate Estrogen Receptor alpha activity is relevant to therapeutics. LATS2 modulates Estrogen Receptor alpha-regulated gene transcription, through direct and/or indirect interactions with Estrogen Receptor alpha. PMID: 23267128
43. LATS2 played important roles in mediating miR-93 functions associated with angiogenesis and metastasis by silencing. PMID: 23111389
44. LATS2 represses reprogramming in cells by post-transcriptionally antagonizing TAZ but not YAP, two downstream effectors of the Hippo pathway. PMID: 22286172
45. Lats2 kinase as a novel regulator of Snail1 protein level, subcellular localization, and thus, activity PMID: 21952048
46. MicroRNA-31 regulated by the extracellular regulated kinase is involved in vascular smooth muscle cell growth via large tumor suppressor homolog PMID: 22020941
47. AMOTL2 is as a novel activator of LATS2. PMID: 21832154
48. the results suggest that the Aurora A-Lats1/2-Aurora B axis might be a novel pathway that regulates accurate mitotic progression by ensuring the proper mitotic localization of Lats2. PMID: 21822051
49. Results reveal a functional connection between the pRB and Hippo tumor suppressor pathways, and suggest that low levels of LATS2 may undermine the ability of pRB to induce a permanent cell cycle arrest in tumor cells. PMID: 21498571
50. Inactivation of LATS2 is one of the key mechanisms for constitutive activation of YAP, which induces deregulation of MM cell proliferation. PMID: 21245096
顯示更多

收起更多
亞細(xì)胞定位：

Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole. Nucleus. Note=Colocalizes with AURKA at the centrosomes during interphase, early prophase and cytokinesis. Migrates to the spindle poles during mitosis, and to the midbody during cytokinesis. Translocates to the nucleus upon mitotic stress by nocodazole treatment.
蛋白家族：

Protein kinase superfamily, AGC Ser/Thr protein kinase family
組織特異性：

Expressed at high levels in heart and skeletal muscle and at lower levels in all other tissues examined.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 6515

OMIM: 604861

KEGG: hsa:26524

STRING: 9606.ENSP00000372035

UniGene: Hs.78960

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human